40th Annual J.P. Morgan Healthcare Conference Presentation
M&A is Accelerating Expansion, Elevating our Presence
We continue to pursue strategic acquisitions
that meet our strict criteria:
■ Technology leadership
▪ Strengthens, expands Repligen's
market position
Underinvested in a key area
Strong revenue growth, margins in line
with or above corporate average
Potential to be accretive to adjusted
EPS in first full year post-acquisition
R REPLIGEN
Analytics
Areas of Investment to Accelerate Growth
Commercial Operations
Acquisition
C Technologies
May 2019
Highly differentiated, in-line, real-time, fast and accurate
measurement; analytics entry
R&D
ARTESYN
Biosolutions
December 2020
Premier integrated systems for filtration and chromatography
Polymem S.A.
June 2021
World class hollow-fiber; immediately expands HF capacity 3x-4x
Avitide Inc.
Sept. 2021
Leading-edge content player; largest most diverse ligand library,
gene-therapy affinity resin focus
Filtration Chromatography
Proteins & Affinity Resins
7View entire presentation